Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

CureVac (Group)

CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is advancing the field of mRNA-based vaccination. The company uses its technology platforms for the development of novel therapeutic mRNA vaccines (RNActive®) for cancer and prophylactic vaccines for infectious diseases. Furthermore CureVac develops adjuvants based on non-coding RNAs (RNAdjuvant®) for enhancing the immune response of other vaccines. The company has successfully completed Phase I/IIa studies with its RNActive® cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. CureVac is currently running a number of clinical trials with its RNActive® vaccines, including a large randomized Phase IIb clinical trial in prostate cancer. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur,In-Cell-Art and Janssen Pharmaceuticals for the development of prophylactic vaccines in infectious diseases utilizing its RNActive® technology platform. *

 

Period Start 2000-08-01 established
  Predecessor University of Tübingen (Eberhard-Karls-Universität)
Products Industry RNAi technology
  Industry 2 RNActive® vaccination technology
Persons Person Haas, Franz-Werner (CureVac 202008– CEO joined 201206 as COO before Sygnis + Lion BIoscience)
  Person 2 Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)
     
Region Region Tübingen
  Country Germany
  Street 15 Friedrich-Miescher-Str.
  City 72076 Tübingen
  Tel +49-7071-92053-0
    Address record changed: 2020-12-11
     
Basic data Employees D: 101 to 500 (2017-10-26)
     
    * Document for �About Section�: 
     
   
Record changed: 2020-12-28

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top